February 25, 2019 P.M. Fornasari A task force of regenerative medicine experts established by the American Society of Interventional Pain Physicians (ASIPP) has formulated new guidelines for the safe and effective use of biologics in the management of low back pain. The guidelines, published in Pain Physician, are based on a review of the literature on the
The agency clarified the process for development programs for regenerative medicine therapies. Feb 20, 2019 By Pier Maria Fornasari FDA provided further details in February 2019 on how manufacturers may use expedited development programs for regenerative medicine therapies, clarifying that the category includes gene and Chimeric antigen receptor T cells (CAR-T) therapies, as well as cellular
Significant improvement in vision in first cohort of Phase II subjects in US trial of hRPC cell therapy in retinitis pigmentosa ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the ongoing Phase I/II clinical trial of its hRPC cell
Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price range is between $310,000-$900,000 using standard methodology but as high as $1.5 million using alternative measures of health gain —— As with all treatments for ultra-rare conditions, judgments of overall value require consideration of contextual issues and broader
Highlights •Microbiome-derived NO promotes widespread S-nitrosylation of the host proteome •Interspecies S-nitrosylation regulates miRNAs, gene expression and host development •Microbiota control host function by shaping the post-translational landscape Summary Bioactive molecules can pass between microbiota and host to influence host cellular functions. However, general principles of interspecies communication have not been discovered. We show here
Advanced Therapies (Advanced Therapies Medicinal Products and Biologised Medical Devices – ATMP/bio-MD) are a potential game changer in health care: They aim to transform the current focus on “treatment of disease” into one that concentrates on “regeneration of health”. The unifying goal of RESTORE is the implementation of newly developed Advanced Therapies in clinical routine
Allogeneic CAR-Ts could serve an important niche – particularly for patients who can’t receive autologous CAR-Ts – but the earliness of the data makes conclusions tough to draw. Since their transition from small, academic clinical trials to commercial production, CAR-T cell therapies have won recognition as a novel and highly effective therapeutic modality, particularly in
The three companies announced a slew of pilots employing machine learning, collaborative digital tools and blockchain technology. A year after Microsoft, Takeda and Eurordis announced that they were teaming up on an innovation initiative to solve the issue of diagnosing children with rare diseases, the partners have unveiled an actionable recommendation report and three new
The 3D printing and AI startup Aether has reached a two-year joint agreement with Procter & Gamble to further develop its AI-driven 3D bioprinting system into an “intelligent robotic craftsman”. Procter & Gamble, the multinational consumer goods giant, has agreed to a two-year developmental agreement with the San Francisco-based 3D printing and AI startup Aether.
Research led by Johns Hopkins investigators has uncovered the roles of two types of cells found in the vessel walls of fat tissue and described how these cells may help speed bone repair. The study found that one of these perivascular stem cell types, pericytes, induces growth of new blood vessels, while another type, adventicytes,
